Table 2. Characteristics of trials included in the meta-analysis.
Authors | AAS (N°) |
Controls (N°) |
Study area | Population type | Type of controls | Type of AAS | Follow-up (wk) |
Mean age (y) |
---|---|---|---|---|---|---|---|---|
Aakvaag and Stromme, 1974 [9]a | 10 | 11 | Norway | Normal subjects | Normal subjects | Mesterolone | 8 | |
Strauss et al, 1983 [10] | 20 | 7 | USA | Bodybuilders | Bodybuilders | Mixed | 27.7 | |
Alén et al, 1985 [11] | 5 | 6 | Finland | Not specified athletes | Not specified athletes | Mixed | 26 | 26.3 |
Yesalis et al, 1988 [12] | 15 | - | USA | Weightlifters | - | Mixed | - | 27 |
Knuth et al, 1989 [13] | 19 | 10 | Germany | Bodybuilders | Bodybuilders | Mixed | - | 26.7 |
Moss et al, 1993 [14] | 15 | - | USA | Amateur body building athletes | - | Mixed | - | 25.2 |
Evans, 1997 [15] | 100 | - | UK | Bodybuilders | - | Mixed | - | From 16 up to >40 |
Korkia and Stimson, 1997 [16] | 97 | - | UK | Amateur athletes | - | Mixed | - | 27.3 |
Torres-Calleja et al, 2001 [17] | 15 | 15 | Mexico | Bodybuilders | Bodybuilders | Mixed | 8.7 | 26.3 |
Fudala et al, 2003 [18] | 88 | - | USA | Not specified athletes | - | Mixed | - | 18–59 |
Perry et al, 2005 [19] | 207 | - | USA | Bodybuilder and other athletes | - | Mixed | - | 27.2 |
Taher et al, 2008 [20] | 15 | 15 | Iran | Bodybuilders | Healthy sedentary | Mixed | - | - |
Ip et al, 2010 [21] | 506 | - | USA | Mixed population: recreational exercisers, competitive bodybuilders, competitive weightlifters, competitive athletes | Mixed population: recreational exercisers, competitive bodybuilders, competitive weightlifters, competitive athletes | Mixed | 260 | 29.3 |
Al-Janabi et al, 2011 [22] | 15 | 15 | Iraq | Bodybuilders | Bodybuilders | Mixed | - | 15–28 |
Coward et al, 2013 [23] | 80 | - | USA | Bodybuilders | Bodybuilders | Mixed | - | 40.4 |
Razavi et al, 2014 [24] | 72 | - | Iran | Not specified abusers | - | Mixed | From <6 months up to >12 years | 25.5 |
Rasmussen et al, 2016 [25], 2017 [26], 2018 [27] | 37 | 30 | Denmark | Not specified abusers | Healthy volunteers | Mixed | 142.3 | 31.4 |
Baggish et al, 2017 [28] | 86 | 54 | USA | Weightlifters | Weightlifters | Mixed | 384 | 42 |
Bordin et al, 2017 [29] | 20 | 20 | Brazil | Soccer and body builder professional athletes | Non abuser professional athletes | Mixed | 21–27 | |
Barbosa Neto et al, 2018 [30] | 15 | 15 | Brazil | Bodybuilders | Healthy volunteers | Mixed | 197.6 | |
Horwitz et al, 2019 [31] | 545 | - | Denmark | Tested positive for AAS in Danish Fitness centres |
- | Mixed | - | 26.2 |
Smit and de Ronde, 2018 [32] | 180 | - | Netherlands | Not specified abusers | - | Mixed | - | 34 |
Souza et al, 2019 [33] | 20 | 10 | Brazil | Not specified abusers | Healthy sedentary subjects | Mixed | 104 | 29 |
Börjesson et al, 2020 [34] | 16 | 5 | Sweden | Mixed athletes | Past AAS users | Mixed | 208 | 33 |
UK: United Kingdom, USA: United States of America, AAS: anabolic androgenic steroids.
aRandomized controlled trial.